BPC-157 and TB-500: My Healing Protocol

BPC-157 and TB-500 are the most over-hyped peptides in the men’s health space. Every forum thread promises miraculous tendon healing, rapid recovery from injuries that had been stuck for months, and a general Wolverine-adjacent regenerative capability. The marketing at some clinics is not much better. You can find men online claiming that these peptides are the reason they healed from ACL tears, rotator cuff injuries, and chronic tendonitis that had not responded to anything else.

The actual published evidence is much more modest. This article is what I ran, what I actually experienced, and what I am willing to claim about the result. The goal is to give you the honest version of what this category looks like from inside a first-person protocol so you can decide whether to run your own experiment with calibrated expectations.

For the baseline on peptides, see Peptides: A No-BS Primer. For the regulatory context that affects access to these compounds, see Peptide Access After the Kennedy HHS Announcement and the peptides wiki.

What the evidence says

Before describing my protocol, it is worth being clear about what the literature actually supports.

BPC-157 (Body Protection Compound 157) is a 15-amino-acid peptide originally isolated from human gastric juice. The proposed mechanism involves angiogenesis (new blood vessel formation), growth factor signaling, and nitric oxide modulation. The research base is dominated by a single research group in Croatia led by Predrag Sikiric, which has published dozens of papers since the 1990s on BPC-157 effects in rats. The rat studies show remarkable effects on tendon healing, gut repair, and various injury models. The concentration of the research in a single lab is itself a red flag from a replication standpoint.

Human data for BPC-157 is almost nonexistent. A few small human studies have looked at safety and pharmacokinetics. I am not aware of any well-designed RCTs in humans that have demonstrated clinical efficacy for the injury healing use case that the compound is marketed for. This is not because the compound does not work in humans. It is because the trials have not been done.

TB-500 (Thymosin Beta-4 fragment) is a 43-amino-acid peptide fragment derived from thymosin beta-4, a naturally occurring protein involved in cell migration, wound healing, and tissue repair. The animal research on TB-500 is suggestive of wound healing and tissue repair effects, particularly in cardiac and corneal tissue. Like BPC-157, the human evidence is thin. Some clinical trials of full-length thymosin beta-4 (not the TB-500 fragment) have been run in stroke and cardiac applications, with mixed results.

When I say “the evidence is thin,” I am not saying the mechanisms are implausible or that the animal data is garbage. The mechanisms are plausible and the animal data is interesting. I am saying that the gap between “rat studies with surgically induced injuries” and “40-year-old man with a stubborn shoulder issue” is not one the published literature has bridged. Using these compounds is a decision to extrapolate from animal data to your own body, with all the uncertainty that implies.

Why I ran the protocol anyway

I had a shoulder issue. Specifically, a supraspinatus tendinopathy that developed after a period of overhead pressing volume I should not have been doing. The pain was mild at first, got worse over two months, and then plateaued at a level that was stable but annoying. Bench press was painful. Overhead press was out. Pull-ups were uncomfortable. Simple daily movements (putting on a jacket, reaching for a high shelf) triggered the pain reliably.

I did the standard things. Three months of physical therapy. Corrective exercises. Rest from the aggravating movements. Eccentric loading protocols. A cortisone injection offered by my PCP, which I declined because I did not want to mask the pain without addressing the underlying tissue issue. I followed the PT protocol faithfully for 12 weeks. The improvement was real but slow, maybe 30-40% better than baseline but not resolved.

At that point, I was at the decision point for most men with a stuck injury: continue the conservative protocol for another 3-6 months and hope it resolves, consider a more aggressive intervention like a cortisone injection or PRP, or try something off the standard menu. I chose the off-menu option because the downside was small, the potential upside was meaningful, and the protocol I was considering was legal through a real 503A pharmacy with a prescription from my provider.

I want to be clear that this was my decision with my provider’s involvement, not a recommendation. My situation was specific and my tolerance for experimental interventions with weak human evidence was deliberate. Your situation and your tolerance may be different.

The protocol

Six weeks. Subcutaneous injection daily. The dosing and combination I chose was:

• BPC-157: 250 mcg once daily, subcutaneous, injected near the shoulder (in the subcutaneous tissue of the upper arm or lateral deltoid area, not intramuscular). The theory behind injecting near the site of injury is that some of the research suggests local effects may be part of the mechanism, though the evidence for systemic vs. local injection producing different outcomes is thin.
• TB-500: 2 mg once weekly, subcutaneous, injected anywhere (systemic distribution is the theory, no site-specific advantage).

I continued the PT exercises, modified training to avoid the aggravating movements, and kept everything else about my routine the same. Sleep, nutrition, and other protocol elements stayed constant. No other new interventions.

The compound was sourced from a PCAB-accredited 503A compounding pharmacy through my DPC physician. My provider reviewed the evidence with me, acknowledged the uncertainty, and wrote the prescription with the understanding that it was an experimental use. Total cost for the 6-week protocol was around $280 for both peptides combined.

What happened

The first two weeks, nothing. I kept looking for any change and finding none. The pain was the same. The range of motion was the same. I did not expect anything in the first two weeks based on the reported timelines, but the absence of change made me question whether this was going to work at all.

Week three, the first noticeable change. The morning stiffness I had been experiencing (the shoulder would be stiffer for the first hour after waking up, then loosen) reduced. Not eliminated, but noticeably less. I could not have produced this as a confident subjective report if I had not been tracking it, but it was real.

Week four, the more noticeable change. The pain with specific movements started to reduce. Overhead reach was still not good, but the pain with bench press at light weight was meaningfully less. The pain with simple daily movements (putting on a jacket) was largely gone.

Week five and six, continued improvement on a gradient. By the end of week six, the pain was 80-90% resolved. Bench press at moderate weight was comfortable. Overhead press at light weight was possible without pain. The morning stiffness was gone. The affected range of motion was close to pre-injury.

I kept running the PT exercises and the modified training for another four weeks after stopping the peptides. The improvement held. By the time I tried a more aggressive overhead pressing session at the 12-week mark from starting the protocol, I was able to press close to my pre-injury weight without pain.

What I can and cannot claim

Here is where I have to be careful about what the result actually tells me.

What the timeline suggests. The injury had been stuck at the 30-40% improvement level for a month before I started the protocol. The rate of improvement during the protocol was much faster than the preceding month. That is suggestive of something new in the picture.

What the timeline does not prove. Tendinopathies heal on their own with time and conservative management. The recovery that happened during the protocol might have happened anyway during those six weeks. I have no control arm. I have no way to know what the trajectory would have looked like without the peptides.

The placebo confound. I had chosen to try an intervention I hoped would work. Expectation effects are real, especially for subjective outcomes like pain. Some of the improvement I attributed to the protocol might have been placebo-driven or attention-driven. I cannot rule this out.

The regression-to-the-mean confound. The injury had plateaued for a month at a stable but elevated pain level. Stable plateaus often precede natural resolution. The fact that I started a new intervention right before improvement happened does not prove the intervention caused the improvement.

The structured protocol confound. Starting the peptide protocol also made me more attentive to the injury. I was more careful about movement. I was tracking symptoms more carefully. I was more consistent with the PT. It is possible that the added attention and consistency contributed to the improvement independent of the peptides.

What I am willing to say: the protocol resolved faster than I expected and faster than the preceding month’s trajectory would have predicted. I believe it probably helped. I cannot prove it helped. I would run it again in a similar situation because the downside was small and the cost was manageable, but I would not recommend it as a guaranteed solution to anyone.

What I would do differently

Track more structured data. I did loose notes. A structured daily pain and range-of-motion rating would have made the before-and-after comparison more rigorous. If I were running this again, I would use a 10-point pain scale recorded daily and a simple range-of-motion measurement weekly.

Try BPC-157 alone first, then add TB-500. Running both peptides simultaneously means I cannot attribute any effect to one or the other. A cleaner experiment would have been BPC-157 for 3 weeks, then adding TB-500 for the next 3 weeks, with the data from each phase compared.

Run it earlier. I waited until the conservative protocol had plateaued for a month. Earlier in the injury course, the baseline rate of healing is higher, and the signal-to-noise ratio for an added intervention is worse. If I were using this again, I would either run it very early (when the injury was acute and conservative management was starting) or very late (when the conservative protocol had clearly failed). The middle is the worst time to measure an effect.

Document my starting point more carefully. I did not get imaging before starting. A baseline MRI or ultrasound would have been useful for comparing tissue quality at the end. This is expensive and probably not necessary for most men, but for a more rigorous experiment, it would be worth considering.

The framing I would give someone else

If you are considering a BPC-157 or TB-500 protocol, here is how I would frame it.

Understand that the human evidence is thin. You are extrapolating from rat studies. The mechanism is plausible. The outcome is not guaranteed.

Treat it as an experiment with a clear endpoint. 4-6 weeks is a reasonable first trial. Define what you are measuring before you start. Stop at the endpoint and evaluate honestly.

Use a real 503A pharmacy. Do not use gray market research peptides. The cost savings are not worth the quality uncertainty. Work with a provider who will write a prescription through a reputable compounding pharmacy.

Do not stack with other new variables. If you are trying to figure out whether BPC-157 helped a specific injury, do not also change your PT protocol, add new supplements, and start new training. Change one thing at a time.

Be honest about the result. The desire for a new intervention to work is a powerful confound. If you run the protocol and cannot tell whether it helped, the right answer is “I cannot tell,” not “I think it probably helped a little.”

Do not expect this to replace the boring things. Healing peptides are not a substitute for PT, for rest, for sleep, for nutrition, or for load management. They are a possible small lever on top of the foundation.

The honest framing

Healing peptides might work in humans. The animal evidence is interesting. The mechanisms are plausible. The human RCT data is not there yet. Anyone who tells you BPC-157 is proven in humans is overselling it. Anyone who tells you it does not work at all is overselling the other direction.

My specific experience with a specific injury was consistent with the peptides helping, but the experiment was not rigorous enough to prove anything, and I will not claim more than that. Your mileage may vary. The category is worth considering as a time-limited experiment for specific stuck issues where the conservative protocol has plateaued and the downside of trying something experimental is small. It is not worth considering as a routine part of a protocol or as a substitute for the interventions with real evidence.

Run the experiment if the situation warrants it. Track it honestly. Do not oversell the result to yourself or anyone else.